Literature DB >> 1750185

Pathology of septum formation in primary biliary cirrhosis: a histological study in the non-cirrhotic stage.

Y Nakanuma1.   

Abstract

Bridging or incomplete septum formation, an important step leading to cirrhosis in various chronic progressive liver diseases, was examined in 231 liver biopsy specimens of primary biliary cirrhosis (non-cirrhotic stage. Incomplete septa from the enlarged portal tracts and portal to portal bridges were frequent and appeared first, while portal to central ones appeared subsequently and became frequent in the liver specimens with changes resembling cirrhosis. These septa were divided into four types histologically: ductular, lymphocytic, loose connective tissue and fibrous type. More than one type was usually found in the same specimen. The pathology of the first three types was similar to and frequently continuous with that of neighbouring periportal regions, suggesting that most of these septa were formed by the extension of periportal destructive processes. The fibrous type might be an advanced form of the other three types. Incomplete septa seemed to pinch off part of the hepatic parenchyma in a hepatic lobule; this was followed by an unusual enlargement of the portal tracts and an approximation of portal tracts and central veins. There were perivenular hepatocellular necroses on occasion. Progression of periportal hepatocellular damage may lead to septum formation and finally progress to cirrhosis, in primary biliary cirrhosis. The significance of perivenular necroses remains speculative.

Entities:  

Mesh:

Year:  1991        PMID: 1750185     DOI: 10.1007/bf01605071

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  13 in total

1.  Immunohistochemical study on bile ductular proliferation in various hepatobiliary diseases.

Authors:  Y Nakanuma; G Ohta
Journal:  Liver       Date:  1986-08

Review 2.  Primary biliary cirrhosis.

Authors:  E R Dickson; C R Fleming; J Ludwig
Journal:  Prog Liver Dis       Date:  1979

3.  Chronic active liver disease. The range of histologic lesions, their response to treatment, and evolution.

Authors:  A H Baggenstoss; R D Soloway; W H Summerskill; L R Elveback; L J Schoenfield
Journal:  Hum Pathol       Date:  1972-06       Impact factor: 3.466

4.  Nodular hyperplasia of the liver in primary biliary cirrhosis of early histological stages.

Authors:  Y Nakanuma; G Ohta
Journal:  Am J Gastroenterol       Date:  1987-01       Impact factor: 10.864

5.  Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

Authors:  R Poupon; Y Chrétien; R E Poupon; F Ballet; Y Calmus; F Darnis
Journal:  Lancet       Date:  1987-04-11       Impact factor: 79.321

6.  Orcein positive granules in the hepatocytes in chronic intrahepatic cholestasis. Morphological, histochemical and electron X-ray microanalytical examination.

Authors:  Y Nakanuma; T Karino; G Ohta
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1979-05-14

7.  Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients.

Authors:  B Portmann; H Popper; J Neuberger; R Williams
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

8.  Immunohistochemical characterization of inflammatory infiltrates in primary biliary cirrhosis.

Authors:  J J van den Oord; J Fevery; J de Groote; V J Desmet
Journal:  Liver       Date:  1984-08

9.  The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis.

Authors:  W G Cooksley; R A Bradbear; W Robinson; M Harrison; J W Halliday; L W Powell; H S Ng; C S Seah; K Okuda; P J Scheuer
Journal:  Hepatology       Date:  1986 May-Jun       Impact factor: 17.425

10.  Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.

Authors:  Y Matsuzaki; N Tanaka; T Osuga; T Aikawa; J Shoda; M Doi; M Nakano
Journal:  Am J Gastroenterol       Date:  1990-01       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.